fig1

Figure 1. Novel and old perspectives for HCC surveillance. Liver biopsy and ultrasound are currently the most used procedures to detect HCC, but these techniques harbor several limitations. Liquid biopsy offers a simple and non-invasive alternative and provides a wide range of potentially relevant molecules for tumor surveillance. Biochemical, epigenetic, and genetic biomarkers can be isolated from peripheral blood, and they are currently exploited in the HCC setting to ameliorate their detection. These markers can discriminate NAFLD stages, predict early HCC onset, and dynamically follow cancer evolution and metastasis.